Abstract

Sickle cell anemia is a unique disease dominated by hemolytic anemia and vaso-occlusive events. The latter trigger a version of ischemia/reperfusion (I/R) pathobiology that is singular in its origin, cyclicity, complexity, instability, perpetuity, and breadth of clinical consequences. Specific clinical features are probably attributable to local I/R injury (e.g., stroke syndromes) or remote organ injury (e.g., acute chest syndrome) or the systematization of inflammation (e.g., multifocal arteriopathy). Indeed, by fashioning an underlying template of endothelial dysfunction and vulnerability, the robust inflammatory systematization no doubt contributes to all sickle pathology. In this Review, we highlight I/R-targeting therapeutics shown to improve microvascular blood flow in sickle transgenic mice undergoing I/R, and we suggest how such insights might be translated into human therapeutic strategies.

MeSH

Cells, Anemia, Sickle Cell, Anemia, Reperfusion, Therapeutics, Ischemia

Cited by

• Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance. Haematologica, 2021
• Improving the ischemia-reperfusion injury in vascularized composite allotransplantation: Clinical experience and experimental implications. Front Immunol, 2022
• Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine (Baltimore), 2024
• Missing the mark(ers): circulating endothelial cells and endothelial-derived extracellular vesicles are elevated in sickle cell disease plasma. Front Immunol, 2025
• IL-6 levels are dramatically high in the sputum from children with sickle cell disease during acute chest syndrome. Blood Adv, 2021
• Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis. Syst Rev, 2024
• Soluble MD-2 and Heme in Sickle Cell Disease Plasma Promote Pro-Inflammatory Signaling in Endothelial Cells. Front Immunol, 2021
• Heme Burden and Ensuing Mechanisms That Protect the Kidney: Insights from Bench and Bedside. Int J Mol Sci, 2021
• A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. Blood, 2022
• MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease. Blood Adv, 2021
• Sickle cell disease mice have cerebral oxidative stress and vascular and white matter abnormalities. Blood Cells Mol Dis, 2021
• Mouse models of sickle cell disease: Imperfect and yet very informative. Blood Cells Mol Dis, 2023
• Circulating mitochondrial DNA is a proinflammatory DAMP in sickle cell disease. Blood, 2021
• Sickle cell vaso-occlusion: The dialectic between red cells and white cells. Exp Biol Med (Maywood), 2021
• Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial. JAMA, 2021
• Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease. Front Immunol, 2021
• Sickle Cell Disease: A Paradigm for Venous Thrombosis Pathophysiology. Int J Mol Sci, 2020
• Multiple inducers of endothelial NOS (eNOS) dysfunction in sickle cell disease. Am J Hematol, 2021
• Chronic organ injuries in children with sickle cell disease. Haematologica, 2021
• MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease. Transl Res, 2022